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ABSTRACT
Background: Vascular endothelial growth
factor (VEGF) and related pathway elements
are critically important in the pathogenesis,
growth, and development of solid tumors.
Inhibiting the VEGF signaling pathway is
being investigated as a therapeutic strategy for
cancer, either by blockade of VEGF ligand
binding or inhibition of the VEGF receptor.
Aflibercept is a VEGF inhibitor that has been
approved by the US Food and Drug
Administration for the treatment of macular
degeneration and metastatic colorectal cancer
(mCRC).
Methods: A search of PubMed and MEDLINE
from January 2000 to August 2013 was
performed using the following terms (or
combination of terms): VEGF, colorectal
cancer, mCRC, aflibercept, ziv-aflibercept.
Studies were limited to those published in
English.
Results: Phase 1 and 2 clinical trials of
aflibercept in advanced non-hematological
cancer showed acceptable safety and provided
justification for further investigation. Four
phase 3 clinical trials were conducted to
evaluate aflibercept for the treatment of
different cancers. The VELOUR trial evaluated
aflibercept with FOLFIRI in patients with
mCRC. The addition of aflibercept resulted in
improved median overall survival (OS, 13.5 vs.
12.1 months, p = 0.0032). The VITAL trial
evaluated docetaxel plus aflibercept vs.
docetaxel plus placebo in patients with non-
small cell lung cancer (NSCLC) who had
progressed after first-line platinum-based
chemotherapy; there was no significant
difference between the two treatment groups
in terms of OS. The VANILLA trial in patients
with metastatic pancreatic adenocarcinoma was
terminated because addition of aflibercept to
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gemcitabine failed to demonstrate improved OS
in an interim analysis. In patients with
metastatic androgen-independent prostate
cancer, the VENICE trial also failed to
demonstrate an increase in OS when
aflibercept was combined with standard first-
line chemotherapy. The most common adverse
events associated with aflibercept in these trials
were hypertension, venous and arterial
thromboembolic events, hemorrhage, and
proteinuria.
Conclusions: In patients with mCRC,
aflibercept demonstrated an improvement in
OS when added to FOLFIRI. However, it has
failed to show similar benefits in other tumor
types. Further investigation is needed to
improve patient selection and to distinguish
patients who may benefit best from aflibercept
from those who will require other anti-
angiogenic agents.
Keywords: Adverse events; Aflibercept;
Colorectal cancer; Tumor angiogenesis;
Vascular endothelial growth factor
INTRODUCTION
Therapeutic options for patients with cancer,
such as melanoma, prostate cancer, and renal
cell carcinoma, have increased during the past
decade because of improved understanding of
tumor biology and availability of targeted
agents. Vascular endothelial growth factor
(VEGF) and related signaling pathways are
considered critically important in the
pathogenesis, growth, and development of
cancer. Inhibiting the VEGF signaling pathway
has been investigated as a therapeutic strategy
for cancer, either by blockade of VEGF ligand
binding or inhibition of the VEGF receptor
(VEGFR) [1].
Vascular Endothelial Growth Factor
A prevailing hypothesis is that when a tumor
outgrows its blood supply, the resulting
hypoxia switches on hypoxia inducible factor
(HIF) a signaling that stimulates the production
of several pro-angiogenic factors [1, 2]. An
important pro-angiogenic pathway is that
mediated by the VEGF family of ligands,
which includes six growth factors [VEGF-A,
VEGF-B, VEGF-C, VEGF-D, VEGF-E, and
placental growth factor (PlGF)] and three
VEGF receptors [2–4]. The VEGFRs are
transmembrane tyrosine kinases present
mainly in endothelial cells. When circulating
VEGFs bind to VEGFRs, signal transduction
pathways are activated that may promote
endothelial cell proliferation, differentiation,
migration, and angiogenesis [3]. The VEGF/
VEGFR signaling pathway is involved in
normal developmental and wound healing
processes such as embryologic development,
skeletal growth, and wound healing [4].
In addition, it has been shown that tumor
angiogenesis is usually ‘dysfunctional’, with
profound alterations, in terms of shape, size,
and permeability, as compared to normal
angiogenesis [5]. Anti-angiogenic treatments
may lead to, not only inhibition of
angiogenesis, but also normalization of such
abnormal vasculature, allowing, for example,
better extravasation of anticancer drugs in
tissues. Such a phenomenon appears to be
critical in colorectal cancer (CRC), where
indeed anti-angiogenic treatments, such as
bevacizumab, are commonly administered in
an adjunction to cytotoxic chemotherapy [5].
Furthermore, VEGF expression in CRC may
be associated with metastasis, recurrence, and
poor prognosis [6–8]. Therefore, inhibitors of
VEGF or VEGFRs were developed to treat
malignancies by limiting tumor angiogenesis
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associated with activated VEGF/VEGFR
pathways. Here, we review the rationale and
clinical development of aflibercept for the
treatment of cancer with particular emphasis
on its use in CRC.
METHODS
A search of PubMed and MEDLINE from January
2000 to August 2013 was performed using the
following terms (or combination of terms):
VEGF, colorectal cancer, metastatic colorectal
cancer (mCRC), aflibercept, ziv-aflibercept.
Studies were limited to those published in
English.
We also reviewed reference lists and
discussed search results with experts. Due to
its novel nature, abstracts or presentations of
any national or international conference on
aflibercept were assessed for inclusion.
VEGF-BINDING AGENTS
Aflibercept (VEGF Trap)
Aflibercept, also known as ziv-aflibercept or
VEGF Trap (Zaltrap, Regeneron,
Pharmaceuticals, Tarrytown, NY, USA and
Sanofi, Bridgewater, NJ, USA), has been
approved by the US Food and Drug
Administration for the treatment of macular
degeneration and mCRC [9–11]. Aflibercept is
a fusion compound that includes human
VEGFR1 (FLT1), extracellular immunoglobulin
(Ig) domain number 2, and VEGFR2 (KDR)
extracellular Ig domain number 3, fused to
human IgG1 Fc (Fig. 1) [12]. This fusion
protein acts as a soluble decoy receptor that
binds (‘‘traps’’) VEGF and prevents VEGF
binding and signaling. Aflibercept binds to
VEGF with high affinity (Kd% 1 pmol/L) and
also binds to PlFGs [13, 14].
Some tumors may become resistant to anti-
VEGF therapies because of an increase in the
levels of PlGF [13]; therefore, it is feasible that
the binding of aflibercept to PlGF could be of
interest because by binding or ‘‘trapping’’ both
VEGF and PlGF aflibercept could possibly
overcome the development of resistance to
other drugs such as bevacizumab [14]. In
preclinical studies, aflibercept prevented the
growth of micrometastases, caused regression
and renormalization of vasculature in existing
tumors, and inhibited new vascular growth [15,
16].
Fig. 1 Schematic structure of aﬂibercept, also known as
ziv-aﬂibercept or VEGF trap. This drug is a fusion
compound that includes human VEGFR1 (FLT1), extra-
cellular Ig domain number 2, and VEGFR2 (KDR)
extracellular Ig domain number 3, fused to the Fc region of
a human IgG1 molecule. IgG immunoglobulin G, VEGF
vascular endothelial growth factor, VEGFR vascular endo-
thelial growth factor receptor. Reproduced with permission
from Ramlau et al. [12]




phosphorylation of VEGFR-2 in human
umbilical vein endothelial cells and VEGF-
induced fibroblast proliferation in vitro [13].
In mice, aflibercept induces regression of
capillaries, cessation of blood flow, and
apoptosis of endothelial cells, and empty
basement membrane sleeves [17, 18]. Several
studies of the effect of aflibercept on tumor
xenografts, including neuroblastoma, Wilms’
tumor, ovarian cancer, pancreatic tumors,
renal cell carcinoma, glioma, and CRC, have
reported anti-angiogenic activity, including
regression of blood vessels, decreased tumor
vessel density and perfusion, inhibition of
metastases, and improved survival [19].
Inhibition of tumor growth and improved
survival were demonstrated for several animal
tumor xenografts when aflibercept was
administered with trastuzumab, docetaxel,




Several phase 1 studies of aflibercept, as a single
agent or in combination with other drugs, were
undertaken (Table 1) [26–34]. In an open-label,
dose-escalation study, 38 patients with relapsed
or refractory solid tumors initially received a
single subcutaneous dose of aflibercept 25 lg/kg
followed 4 weeks later by six weekly injections
(escalating doses 0.025, 0.05, 0.1, 0.2, 0.4, and
0.8 mg/kg) or six twice-weekly injections
(0.8 mg/kg) [30]. In this trial, no objective
responses were observed, but 20 patients (53%)
had stable disease for [1 month and two
patients had stable disease for [1 year. The
most common adverse events (AEs) were
proteinuria (37%), fatigue (32%), injection-site
reaction (18%), nausea (17%), myalgia (16%),
anorexia (16%), hypertension (13%), and voice
hoarseness (11%). Grade 3/4 hypertension (8%
of patients) and proteinuria (3% of patients)
were reported [30].
In another trial evaluating the safety and
efficacy of aflibercept, the agent was
administered intravenously in doses ranging
from 0.3 to 7.0 mg/kg every 2 weeks in 47
patients with refractory solid tumors or non-
Hodgkin’s lymphoma [33]. A partial response
[PR, defined by response evaluation criteria in
solid tumors (RECIST) criteria] [35] was
observed in three patients, and two patients
had stable disease (SD). The most common
toxicities observed were fatigue (63.8%), nausea
(36.2%), and vomiting (27.7%); grade 3
hypertension occurred (16.7% patients at the
2.0 mg/kg dose; 42.9% patients at the 4.0 mg/kg
dose; 75.0% patients at the 5.0 mg/kg dose) and
grade 3 proteinuria was reported (1 patient,
7.0 mg/kg dose) (Table 1).
Phase 2 Trials
Several phase 2 clinical trials have assessed the
safety and clinical activity of aflibercept, alone
or in combination with cytotoxic drugs, in
various solid tumors including CRC, non-small
cell lung cancer (NSCLC), renal cell carcinoma,
ovarian cancer, gynecologic cancer, soft tissue
sarcoma, transitional cell carcinoma,
melanoma, and glioblastoma (Table 2) [36–44].
Aflibercept was evaluated in two major phase
2 clinical trials for the treatment of mCRC [39,
44]. The first of these studies was a two-stage,
multicenter, open-label, trial in 75 patients who
had received prior treatment for the disease
(Table 2) [39]. Patients were categorized into
two groups dependent on previous treatment
(prior bevacizumab, 51 patients; no prior
bevacizumab, 24 patients), and all patients
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received aflibercept (4 mg/kg) intravenously
every 2 weeks. After aflibercept treatment, the
disease control rate (DCR, PR plus SD) and
median PFS were similar in both groups
(Table 2). AEs were common (Table 2). The
authors concluded that aflibercept had modest
activity against refractory or relapsed mCRC,
regardless of prior therapy with bevacizumab.
The second major phase 2 trial was the
AFFIRM trial which was a randomized open-
label trial evaluating the safety and efficacy of
aflibercept and mFOLFOX6 (5-fluorouracil,
leucovorin, oxaliplatin) as first-line treatment
for mCRC [44]. Patients (n = 236) were
randomized to aflibercept (4 mg/kg) plus
mFOLFOX6 or mFOLFOX6 alone every
2 weeks (Table 2). Mean 12-month
progression-free survival (PFS) was 25.8% for
aflibercept plus mFOLFOX6 and 21.2% for
mFOLFOX6 alone (Table 2). Addition of
aflibercept to mFOLFOX6 significantly
increased the objective response rate (ORR,
49.1% vs. 45.9%, p\0.001); however, median
PFS was similar with or without aflibercept, and
patients who received aflibercept had a higher
frequency (53.4% vs. 6.9%) of grade 3/4
hypertension (Table 2).
Phase 3 Trials
To date, four large phase 3 clinical trials have
been conducted to evaluate aflibercept for the
treatment of various cancers (Table 3) [12, 45–
47]. The VELOUR trial evaluated the efficacy
and safety of adding aflibercept to FOLFIRI in
patients with mCRC who had progressed after
previous treatment with oxaliplatin-based
chemotherapy [45]. The primary endpoint of
the study was OS. The trial included 1,226
patients (18 countries) with measurable or
non-measurable disease according to RECIST
criteria, and a Karnofsky performance status of
C70%. Patients were randomized to receive
treatment with FOLFIRI plus placebo or
FOLFIRI plus aflibercept (Table 2). Addition of
aflibercept resulted in improved OS [median
OS 13.5 vs. 12.1 months; hazard ratio (HR)
0.817; p = 0032]. Addition of aflibercept
significantly improved PFS by 2.2 months
(median PFS 6.9 vs. 4.7 months; HR 0.76;
p\0.0001) and ORR (19.8% vs. 11.2%;
p = 0.0001). Pre-specified subgroup analysis
based on prior bevacizumab exposure was
comparable between patients who had or had
not received bevacizumab. Based on this trial,
the US Food and Drug Administration
approved aflibercept for use with FOLFIRI as
second-line treatment for patients with CRC
who had progressed despite oxaliplatin-
containing chemotherapy.
It is noteworthy that two recent phase 3
trials evaluating the addition of bevacizumab to
chemotherapy after first progression in patients
with mCRC (Table 4) [48, 49] reported findings
comparable, in terms of response rate, DCR and
survival, to the results of the VELOUR trial.
In the ML18147 study, patients, depending
on the first-line therapy, received either
oxaliplatin-based or irinotecan-based second-
line chemotherapy. Median PFS was 5.7 vs.
4.1 months (p\0.0001) and median OS was
11.2 vs. 9.8 months (p = 0.0062) in favor of the
bevacizumab group [48]. The BEBYP trial was a
phase 3 study that randomized patients with
unresectable mCRC treated with bevacizumab
plus first-line chemotherapy (fluoropyrimidine,
FOLFIRI, FOLFOX or FOLFOXIRI) to receive a
second-line chemotherapy with FOLFOX or
FOLFIRI (depending on first-line
chemotherapy) alone or in combination with
bevacizumab at 5 mg/kg intravenously every
2 weeks. The study demonstrated an increased
PFS by continuing bevacizumab in second-line
(median PFS was 6.8 vs. 5.0 months, p = 0.0062)
[49].
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VITAL Trial
The VITAL trial was the second large
randomized phase 3 trial to evaluate the
efficacy and safety of aflibercept [12]. This was
a double-blind, placebo-controlled study of
aflibercept as second-line treatment for
patients (n = 913) with NSCLC who had
progressed after first-line platinum-based
therapy (Table 3). OS was the primary
endpoint. Patients received docetaxel plus
aflibercept or docetaxel plus placebo. No
difference was observed between the two
treatment groups in terms of OS (median OS
10.1 vs. 10.4 months with/without aflibercept,
respectively; HR 1.01; p = 0.90) (Table 3).
Median PFS was slightly prolonged in the
aflibercept group (5.2 vs. 4.1 months; HR 0.82;
p = 0.0035). ORR was also higher in patients
who were treated with docetaxel plus aflibercept
compared with patients treated with docetaxel
plus placebo (23.2% vs. 8.8%; p = 0.001).
VANILLA and VENICE Trials
The remaining two phase 3 clinical trials of
aflibercept were conducted in a first-line setting
and in combination with chemotherapy. The
VANILLA trial enrolled patients with metastatic
pancreatic adenocarcinoma, while the VENICE
trial assessed patients with metastatic
castration-resistant prostate cancer [46, 47].
The VANILLA trial was terminated early
because of an estimation of decreased survival
in patients who received aflibercept vs. control
patients (Table 3) [46]. The VENICE trial sought
to discover an added benefit for the use of
aflibercept in patients with metastatic
androgen-independent prostate cancer [47].
The primary endpoint of the study was OS. A
total of 1,224 patients were enrolled. Patients
were randomized into 1:1 ratio to receive
docetaxel/prednisone plus aflibercept or
docetaxel/prednisone plus placebo. There was
no statistically significant difference in OS
between both groups (median OS 22.1 vs.
21.2 months, p = 0.38; respectively); nor in PFS
(6.9 vs. 6.2 months, respectively; p = 0.31).
However, patients in the aflibercept arm
experienced a higher incidence of grade 3/4
AEs (76.9% vs. 48.5%) which led to
discontinuation rates of 43.9% for aflibercept
vs. 20.9% in the placebo arm.
Aflibercept: Adverse Events
Adverse reactions to aflibercept were common
in phase 1 and 2 trials (Tables 1, 2). In the phase
3 VELOUR trial, the tolerability profile for
aflibercept plus FOLFIRI was consistent with
that reported previously for aflibercept,
FOLFIRI, and other anti-VEGF therapies.
Aflibercept was associated with hypertension
(19.1%), proteinuria (7.9%), and other common
chemotherapy-related AEs such as diarrhea,
hand-foot syndrome, and neutropenia [45]. In
the phase 3 VITAL trial, patients who received
aflibercept experienced a higher frequency of
grade 3/4 AEs including neutropenia
(aflibercept 28.0%, control 21.1%); fatigue
(aflibercept 11.1%, control 4.2%); stomatitis
(aflibercept 8.8%, control 0.7%) and
hypertension (aflibercept 7.3%, control 0.9%)
[12].
In the VELOUR trial, the incidence of
treatment-related AEs was similar among
patients who received aflibercept with prior
bevacizumab exposure (AEs, 100% of patients)
or no prior bevacizumab exposure (AEs, 98.9%
of patients). In the aflibercept component of the
study, the frequency of grade 3/4 AEs was
similar between patients who had received
prior bevacizumab (82.5%) and patients who
had no prior bevacizumab experience (83.9%)
14 Rare Cancers Ther (2013) 1:3–19
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[45]. In both groups, 25% of aflibercept-treated
patients discontinued treatment because of AEs.
The most frequent AEs common to aflibercept
and bevacizumab were grade 3/4 neutropenia,
diarrhea, asthenia, infections, and stomatitis;
however, bevacizumab had a more favorable
safety profile with less proteinuria and almost
no gastrointestinal or constitutional toxicity.
The authors of a meta-analysis of three
double-blind, placebo-controlled, phase 3 trials
evaluating AEs associated with aflibercept
concluded that the most common AEs
associated with intravenous aflibercept were
hypertension, venous and arterial
thromboembolic events, hemorrhage, and
proteinuria (Table 5) [50].
BIOMARKERS
Despite extensive efforts, researchers have yet
to identify a reliable and reproducible
biomarker that allows selection and
identification of patients who are most likely
to benefit from aflibercept therapy. Circulating
biomarkers are currently under evaluation as
potential tools to monitor treatment response
to anti-VEGF drugs. For some cancers,
response to treatment with aflibercept may
be monitored by measuring levels of
cytokines, growth factors, and myeloid
biomarkers. In patients with glioblastoma,
treatment with aflibercept was associated
with decreased levels of VEGF and PlGF [51].
Lower levels of growth-regulated oncogene a,
hepatocyte growth factor, and stem cell
growth factor b, and higher levels of free
VEGF, were also associated with a PR in this
patient group. Elevated baseline levels of
CTACK/CCL27, MCP3/CCL7, MIF, and IP-10/
CXCL10, and a decrease in VEGFR1-positive
monocytes from baseline to 24-h post-
aflibercept administration, have also been
associated with improved response in
glioblastoma patients [52].
Table 5 Adverse events associated with aﬂibercept in the treatment of cancer
Adverse event (grade > 3) Aﬂibercept (n5 1,333) Placebo (n5 1,329)
Hypertension 14.6 1.6
Venous thromboembolic events 6.4 6.1
Hemorrhage 1.5 3.1
Arterial thromboembolic events 1.0 1.7
Proteinuria 0.8 6.3
Gastrointestinal perforation 0.2 0.8
Cardiac dysfunction \0.1 0.5
Fistula \0.1 0.2
Osteonecrosis \0.1 \0.1
Impaired wound healing 0 0.2
Data reported as percent patients. Data obtained from meta-analysis of three double-blind, placebo-controlled, phase 3
clinical trials with intravenous aﬂibercept [50]
Meta-analysis of total of 2,662 patients of three double-blind, placebo-controlled, phase 3 trials in patients with metastatic
colorectal, lung and pancreatic cancer




Over the last decade there have been
unprecedented advances in the treatment of
mCRC. In the modern era, the average median
survival duration has doubled, and patients
usually live longer than 2 years largely due to
the availability of new active agents. Last year
alone in 2012, the FDA has approved two new
drugs, aflibercept and regorafenib, for the
treatment of mCRC due to demonstrated
overall survival benefits.
Although, as shown in this review,
aflibercept has demonstrated overall survival
benefits when combined to FOLFIRI for the
treatment of patients with mCRC that is
resistant to or has progressed following an
oxaliplatin-containing regimen, due to the
lack of head to head trials, its place in the
treatment paradigm of mCRC, with the
availability of similar agents such as
bevacizumab, is still not well defined.
Similarly, the best way to combine and
sequence all of these drugs to optimize
treatment has not yet been established. In
some cases, predictive biomarkers can
influence the choice of treatment. For
instance, patients who harbor a K-ras mutation
may benefit from strategies targeting the EGFR
[53]. Despite extensive research, there are no
reliable or reproducible markers that predict
response to anti-angiogenic therapy. These
advances in therapy have not only resulted in
nearly doubling of the median overall survival,
but have also resulted in many challenges and
raised several questions such as: why such
agents have modest clinical success despite the
promising preclinical data? Which VEGF
inhibitor is more potent and better tolerated?
Can these inhibitors be used in combination
and if so, can this type of treatment be
sustained? What are the future promising
agents targeting VEGF and related signaling
pathway and strategies to combat mCRC? How
do these new agents such as aflibercept compare
directly to the older medications such as
bevacizumab and how can we select the
proper agent between the currently available
drugs?
Additionally, the challenge is how to
determine the optimal sequencing of these
agents in treatment naı¨ve patients, relapsed
patients or in the maintenance setting. Lastly
and perhaps most importantly, why aflibercept
has failed to demonstrate similar benefits in
other tumor types such as patients with NSCLC,
prostate or pancreatic cancer and how we can
improve patient selection and distinguish
patients who may benefit best from aflibercept
from those who will require other anti-
angiogenic agents.
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